{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-020677","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.680498+00:00","generated_at":"2026-05-17T00:36:59.685727+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lipocine presents LPCN 2401 Phase 2 data at ObesityWeek showing improved body composition and liver health","bullets":["In Phase 2 trial, LPCN 2401 increased lean mass, reduced fat mass, and improved fat-to-lean ratio vs placebo at 20 and 36 weeks.","Treatment with LPCN 2401 showed rapid reductions in liver fat content and liver injury markers (ALT, AST) starting at 4-8 weeks.","MRI-PDFF demonstrated significant reductions in liver fat at 12 weeks, maintained through week 36.","LPCN 2401 was well tolerated with no concerning safety signals observed through 72 weeks of exposure."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-020677","json":"https://secwatch.observer/filing/0001493152-25-020677.json","markdown":"https://secwatch.observer/filing/0001493152-25-020677.md","text":"https://secwatch.observer/filing/0001493152-25-020677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225020677/0001493152-25-020677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225020677/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:36:59.685727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}